Literature DB >> 18502331

Dysregulated RET signaling in thyroid cancer.

Maria Domenica Castellone1, Massimo Santoro.   

Abstract

Numerous biologic processes and such diseases as cancer depend on activation of tyrosine kinase receptors. The RET tyrosine kinase receptor was discovered two decades ago as a transforming gene and was subsequently implicated in the formation of papillary and medullary thyroid carcinoma. This article examines the data about the mechanism of activation of downstream signal transduction pathways by RET oncoproteins. Collectively, these findings have advanced the understanding of the processes underlying thyroid carcinoma formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502331     DOI: 10.1016/j.ecl.2008.02.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  20 in total

Review 1.  RET TKI: potential role in thyroid cancers.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Caterina Mancusi; Michele Colaci; Libero Santarpia; Clodoveo Ferri
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report.

Authors:  Li Jin Duo; Jiang Rong; Wang Bin; Ma Chun Hua; Sun Li Wei; L V Yuan
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

3.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

4.  Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Authors:  Yoshiyuki Suehara; Maria Arcila; Lu Wang; Adnan Hasanovic; Daphne Ang; Tatsuo Ito; Yuki Kimura; Alexander Drilon; Udayan Guha; Valerie Rusch; Mark G Kris; Maureen F Zakowski; Naiyer Rizvi; Raya Khanin; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-10-10       Impact factor: 12.531

5.  Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.

Authors:  Qiuhong Yang; Ryan Moulder K; Mark S Cohen; Shuang Cai; Laird M Forrest
Journal:  BAOJ Pharm Sci       Date:  2015-01-05

6.  The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma.

Authors:  Jodie Barr; Carol M Amato; Steven E Robinson; Nicole Kounalakis; William A Robinson
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

7.  Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.

Authors:  M N Basaran; M M Tuna; E Karakılıç; B A Doğan; N N İmga; D Berker; S Güler
Journal:  J Endocrinol Invest       Date:  2014-12-12       Impact factor: 4.256

Review 8.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

9.  Drosophila Cancer Models Identify Functional Differences between Ret Fusions.

Authors:  Sarah Levinson; Ross L Cagan
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

Review 10.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.